FindTrial
Sign In

treatment strategy of primary esophageal small cell carcinoma: a multicenter retrospective study

A multicenter retrospective study on the optimal treatment strategy for primary esophageal small cell carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040175
Enrollment
Unknown
Registered
2020-11-24
Start date
2020-11-18
Completion date
Unknown
Last updated
2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary esophageal small cell carcinoma

Interventions

Group 1:radiotherapy and chemotherapy
Group 2:surgery and chemotherapy
conrtol group:chemotherapy

Sponsors

Shandong Cancer Hospital and Institute
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with primary esophageal small cell carcinoma diagnosed from January 2004 to June 2020; 2. Patients received single or combined anti-tumor therapy, including chemotherapy, radiotherapy and surgery; if patients received chemotherapy alone, the cycle of chemotherapy was at least 2 cycles; 3. The patient data are complete and can be used for clinical data analysis.

Exclusion criteria

Exclusion criteria: 1. Esophageal squamous cell carcinoma or adenocarcinoma; 2. Incomplete patient data; 3. The patient did not receive antineoplastic therapy, including more than or equal to two cycles of chemotherapy, radiotherapy or surgery.

Design outcomes

Primary

MeasureTime frame
overall survival;—

Secondary

MeasureTime frame
objective tumor response;progression free survival,;treatment-related toxicities;—

Countries

China

Contacts

Public ContactHongfu Sun

Shandong Cancer Hospital and Institute

ice9892@163.com+86 13583167252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026